Literature DB >> 33879578

Ectonucleotidases in Inflammation, Immunity, and Cancer.

Clarissa Branco Haas1, Marianna Lovászi1, Elizandra Braganhol2, Pál Pacher3, György Haskó4.   

Abstract

Nucleoside triphosphate diphosphohydrolases (NTPDases) are a family of enzymes that hydrolyze nucleotides such as ATP, UTP, ADP, and UDP to monophosphates derivates such as AMP and UMP. The NTPDase family consists of eight enzymes, of which NTPDases 1, 2, 3, and 8 are expressed on cell membranes thereby hydrolyzing extracellular nucleotides. Cell membrane NTPDases are expressed in all tissues, in which they regulate essential physiological tissue functions such as development, blood flow, hormone secretion, and neurotransmitter release. They do so by modulating nucleotide-mediated purinergic signaling through P2 purinergic receptors. NTPDases 1, 2, 3, and 8 also play a key role during infection, inflammation, injury, and cancer. Under these conditions, NTPDases can contribute and control the pathophysiology of infectious, inflammatory diseases and cancer. In this review, we discuss the role of NTPDases, focusing on the less understood NTPDases 2-8, in regulating inflammation and immunity during infectious, inflammatory diseases, and cancer.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Year:  2021        PMID: 33879578     DOI: 10.4049/jimmunol.2001342

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

Review 1.  P2 purinergic receptor dysregulation in urologic disease.

Authors:  Janielle P Maynard; Karen S Sfanos
Journal:  Purinergic Signal       Date:  2022-06-10       Impact factor: 3.950

2.  Extracellular ectonucleotidases are differentially regulated in murine tissues and human polymorphonuclear leukocytes during sepsis and inflammation.

Authors:  Clarissa B Haas; Marianna Lovászi; Pál Pacher; Priscila Oliveira de Souza; Julie Pelletier; Rafael Olive Leite; Jean Sévigny; Zoltán Németh; Elizandra Braganhol; György Haskó
Journal:  Purinergic Signal       Date:  2021-10-04       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.